Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wee Loon Ong

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
JAMA Network Open|November 1, 2021
Evaluation of Hypofractionated Radiation Therapy Use and Patient-Reported Outcomes in Men With Nonmetastatic Prostate Cancer in Australia and New ZealandDavid I Pryor, Jarad M Martin, Jeremy L Millar, et al.
Journal of Medical Radiation Sciences|January 12, 2021
Proximal seminal vesicle displacement and margins for prostate cancer radiotherapyDaryl Lim Joon, Michael Chao, Angelina Piccolo, et al.
BJU International|September 11, 2023
Barriers and enablers of active surveillance for prostate cancer: a qualitive study of cliniciansTrent A Pattenden, Isaac A Thangasamy, Wee Loon Ong, et al.
International Journal of Radiation Oncology, Biology, Physics|July 7, 2023
To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate CancerWee Loon Ong, Patrick Cheung, Hans Chung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 24, 2023
Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancerWee Loon Ong, Melanie Davidson, Patrick Cheung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 8, 2023
Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trialWee Loon Ong, Patrick Cheung, Hans Chung, et al.
International Journal of Radiation Oncology, Biology, Physics|April 1, 2024
Predictors of Tumor Dynamics Over a 6-Week Course of Concurrent Chemoradiotherapy for Glioblastoma and the Effect on SurvivalWee Loon Ong, James Stewart, Arjun Sahgal, et al.
International Journal of Radiation Oncology, Biology, Physics|October 6, 2023
Long-Term Quality-of-Life Outcomes After Prostate Radiation Therapy With or Without High-Dose-Rate Brachytherapy Boost: Post Hoc Analysis of TROG 03.04 RADARWee Loon Ong, John Nikitas, David Joseph, et al.
European Urology Oncology|February 4, 2025
Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective TrialsCristian Udovicich, Patrick Cheung, William Chu, et al.
BJUI Compass|July 22, 2025
A population-based analyses of the evolving management of cN1M0 prostate cancer in the PSMA-PET eraJennifer Ward, Kevin Armstrong, Therese Min-Jung Kang, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
JAMA Network Open|November 1, 2021
Evaluation of Hypofractionated Radiation Therapy Use and Patient-Reported Outcomes in Men With Nonmetastatic Prostate Cancer in Australia and New ZealandDavid I Pryor, Jarad M Martin, Jeremy L Millar, et al.
Journal of Medical Radiation Sciences|January 12, 2021
Proximal seminal vesicle displacement and margins for prostate cancer radiotherapyDaryl Lim Joon, Michael Chao, Angelina Piccolo, et al.
BJU International|September 11, 2023
Barriers and enablers of active surveillance for prostate cancer: a qualitive study of cliniciansTrent A Pattenden, Isaac A Thangasamy, Wee Loon Ong, et al.
International Journal of Radiation Oncology, Biology, Physics|July 7, 2023
To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate CancerWee Loon Ong, Patrick Cheung, Hans Chung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 24, 2023
Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancerWee Loon Ong, Melanie Davidson, Patrick Cheung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 8, 2023
Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trialWee Loon Ong, Patrick Cheung, Hans Chung, et al.
International Journal of Radiation Oncology, Biology, Physics|April 1, 2024
Predictors of Tumor Dynamics Over a 6-Week Course of Concurrent Chemoradiotherapy for Glioblastoma and the Effect on SurvivalWee Loon Ong, James Stewart, Arjun Sahgal, et al.
International Journal of Radiation Oncology, Biology, Physics|October 6, 2023
Long-Term Quality-of-Life Outcomes After Prostate Radiation Therapy With or Without High-Dose-Rate Brachytherapy Boost: Post Hoc Analysis of TROG 03.04 RADARWee Loon Ong, John Nikitas, David Joseph, et al.
European Urology Oncology|February 4, 2025
Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective TrialsCristian Udovicich, Patrick Cheung, William Chu, et al.
BJUI Compass|July 22, 2025
A population-based analyses of the evolving management of cN1M0 prostate cancer in the PSMA-PET eraJennifer Ward, Kevin Armstrong, Therese Min-Jung Kang, et al.
Pageof 7